HOME > BUSINESS
BUSINESS
- Japan Ethical Drug Sales in April-June Down 0.8%, with Harvoni Sales Down 75.6%: QuintilesIMS
August 4, 2017
- LTL Pharma to Take Over 3 Brands from Astellas in October
August 3, 2017
- Meiji Seika Pharma to Transfer 3 Generic Brands to Its Generic Subsidiary
August 3, 2017
- Galderma Transfers Epiduo Gel to Maruho in Japan
August 3, 2017
- 3 Deaths among 85 ADRs Bayer Yakuhin Failed to Report Were Known to Employees at Symposiums
August 3, 2017
- Daiichi Sankyo Inks US$300 Million Settlement Deal over Olmesartan Product Liability Litigation in US
August 3, 2017
- Abilify Maintena Approved for Bipolar I Disorder in US
August 2, 2017
- Astellas Applies for Fidaxomicin for Infectious Enteritis in Japan
August 2, 2017
- Biotech Startup Begins Operations in Takeda’s Shonan Research Center
August 2, 2017
- Bayer Yakuhin Finds 85 Further Cases of Unreported ADRs
August 2, 2017
- No Policy Change in Obtaining Regulatory Approval of Nesp Biosimilar through New Firm: Kyowa Kirin President
August 1, 2017
- August FDA Filing Planned for FGF23 Antibody Burosumab: Kyowa Kirin
July 31, 2017
- Abilify-Jzoloft Combo Filed in Japan: Otsuka
July 31, 2017
- Kyowa Kirin Enjoys Higher Earnings on Benralizumab License Revenue
July 31, 2017
- AZ Labor Tribunal with 3 Employees Falls Apart, Civil Suit to Begin
July 31, 2017
- Rohto to Commence Clinical Trial of Regenerative Medicine Product for Hepatic Cirrhosis
July 31, 2017
- Mitsubishi Tanabe Begins Japan PII/III for Dyskinesia Med
July 28, 2017
- Astellas to Move Away from ADCs, Shuts Agensys Research Operations
July 28, 2017
- 3 Generic Makers Ordered to Pay Damages over Oxarol Patent Infringement
July 28, 2017
- Takeda Gets Rights to Tesaro’s PARP Inhibitor in Japan, Other Markets
July 28, 2017
ページ
Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…